The firms also plan to launch a multiplex test for multiple pathogens, including dengue. 

The company will work with the nonprofit to create a test for resource-poor settings. It is also working under a new NIH grant to add antibiotic susceptibility testing to its system.

The researchers, led by VIB and Ghent University in Belgium, hope to complete a validation study within a year.